GlassScriptPhysician profile
Robert P St Amant
NPI 1104822774
$156,396.93
in general payments reported to CMS, 2019-2025
15 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $13K · 2021: $13K · 2022: $20K · 2023: $49K · 2024: $33K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Travel and Lodging: $6,948 · Food and Beverage: $2,207 · Consulting Fee: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,865.75 |
| Travel and Lodging | $6,947.81 |
| Food and Beverage | $2,206.89 |
| Consulting Fee | $1,206.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $152,596.27 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,691.64 | 2020-2021 | |
| Amarin Pharma, INC. | $809.44 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $374.37 | 2019-2022 | |
| Esperion Therapeutics, INC. | $189.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $152.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $126.78 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.79 | 2021 | |
| Ethicon US, LLC | $86.69 | 2021 | |
| Merck Sharp & Dohme LLC | $80.22 | 2019-2021 | |
| Novo Nordisk INC | $21.72 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $20.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.09 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert St Amant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.